Methods and compositions using listeria for enhancing immunogenicity by prime boost

Abstract

Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.

1 - 49 . (canceled) 
     
     
         50 . A method for immunizing a mammal to induce an immune response to a cancer antigen, comprising:
 immunizing the mammal using a prime-boost regimen, wherein the regimen comprises
 (i) administering to the mammal an effective amount of a prime dose of a recombinant adenovirus vector expressing a nucleic acid that encodes an expressible, immunologically active portion of the cancer antigen; and 
 (ii) following the prime dose administration, administering to the mammal an effective amount of a boost dose of a vaccine comprising an attenuated  Listeria  that encodes the expressible, immunologically active portion of the cancer antigen. 
   
     
     
         51 . A method according to  claim 50 , wherein the recombinant adenovirus vector is administered intratumorally or peritumorally. 
     
     
         52 . A method according to  claim 50 , wherein the recombinant adenovirus vector is administered intravenously. 
     
     
         53 . A method according to  claim 50 , wherein the attenuated  Listeria  is administered intravenously. 
     
     
         54 . A method according to  claim 51 , wherein the attenuated  Listeria  is administered intravenously. 
     
     
         55 . A method according to  claim 52 , wherein the attenuated  Listeria  is administered intravenously. 
     
     
         56 . A method according to  claim 50 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D. 
     
     
         57 . A method according to  claim 51 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D. 
     
     
         58 . A method according to  claim 52 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D. 
     
     
         59 . A method according to  claim 53 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D. 
     
     
         60 . A method according to  claim 54 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D. 
     
     
         61 . A method according to  claim 55 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D. 
     
     
         62 . A method according to  claim 56 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D.